Webseite analysieren afinitor.de
Ads
SEO-Bericht mit Informationen und kostenloser Domain-Bewertung für afinitor.de. Die Domäne hat ihren Sitz in .Der Server wird unter der IP-Adresse 104.18.1.16. Die Domain belegt weltweit den Platz in der Rangliste der Webseiten 21000000. Nach Schätzungen haben wir den Zugang zu potenziellen Gewinnen von über 2 Euro pro Monat für diese Seite. Im Jahresvergleich konnte die Domain afinitor.de mehr als 30 € verdienen. Wenn jemand die Domain kaufen wollte, wäre ein guter Verkaufspreis 300 €.
Diese Daten werden geschätzt und sind nicht zu 100% realistisch. Es handelt sich lediglich um eine Schätzung des Gewinns, je nach Thema und generiertem Datenverkehr von afinitor.de. Die geschätzte Zahl der Besucher für afinitor.de liegt bei 22. Somit würde die Gesamtzahl der Menschen, die diese Seite pro Monat besuchen, bei 655 liegen.
Domain Authority
SEO Score
☰ Bericht Lebenslauf
- Seiten-Speed-Wert
- Geschwindigkeit
- Seitenladezeit
- Strom Ip der Domain
- Seitenzeichensatz
- Insgesamt Keywords
- Anzahl der Links
- Titel: Novartis
- Beschreibung: Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
- Domain Authority
- Monatliche Seitenaufrufe: 655
- Geschätzter Wert: 300 euros
Wir haben einen nützlichen Dienst entwickelt, um Whois-Abfragen durchzuführen. "Whois" ist ein Begriff aus den frühen Tagen des Internets, der auf Unix-Betriebssystemen und Hochschulnetzen basiert. Über die Unix-Konsole wird der Befehl "whois" verwendet, um die Identität des Registranten einer Domain zu ermitteln.
Es ist ein Mittel für Internet-Benutzer, verschiedene Arten von Informationen abzufragen, wie zum Beispiel IP-Adressen, Benutzerdaten und auch Bereichsdaten.
Ads
✦ SEO-Bericht
Titel / Meta tags
Bildanalyse
Ein gutes Beispiel für ein HTML-Bild-Tag:
<img src="nettesbild.jpg" alt="Bildbeschreibung" title="Bild Tooltip"/>
Für eine SEO Leistung müssen Sie einen alternativen Text zu schreiben. Der alternative Text muss das Bild der Inhalt beschreiben. Auch die ALT-Tag wird blinde Menschen verwendet. Ihr Browser erzählen ihnen alles über die Beschreibung des Bildes.
Überschrift
Inhaltsanalyse
Code-Analyse
Wir haben nicht gefunden, Bindestriche (-) oder Unterstrichen (_) in Ihrer URL. Google und Experte domainers empfehlen Domains mit Bindestrichen oder un derscores nicht zu kaufen.
Wenn ein Besucher auf Ihre Website kommt, dürfen Sie nicht scheitern. Der Benutzer möchte Ihre Seite innerhalb einer Sekunde geladen sehen. Wir wissen, dass es manchmal schwierig ist, Inhalte in den ersten Sekunden anzuzeigen, aber wenn der Benutzer zu lange warten muss, können Sie diesen Benutzer verlieren. Wenn Ihre Seite zu langsam ist, werden Sie eine Menge Web-Traffic verlieren. Die Ladezeit Ihrer Website beträgt ms, was eine B-Geschwindigkeit ist. Diese Geschwindigkeit ist nicht in Ordnung und muss verbessert werden, da sie über dem Durchschnitt liegt. Unser Speed-Analysator hat gezeigt, dass www.afinitor.de wie folgt ist:
Eine große Anzahl Ihrer Website-Besucher sind in der Regel in Eile und niemand wartet gerne zu lange, bevor Ihre Website Inhalte lädt. Wenn Ihre Website langsam ist, verlieren Sie viele Besucher. Ihre Homepage-Ladezeit beträgt ms was eine B-Geschwindigkeit ist. Diese Geschwindigkeit ist nicht in Ordnung und muss verbessert werden, da sie über dem Durchschnitt liegt. Unser Speed-Analysator hat gezeigt, dass www.afinitor.de wie folgt ist:
Speed:
Ladezeit der Seite: ms
Der Text/HTML-Verhältnis von 3% auf dieser Seite.
Dieses Verhältnis festige den Prozentsatz zwischen dem menschlichen Text und alle HTML-Elemente, Image-Tags und andere nicht sichtbare Informationen. Ein guter Text / HTML-Verhältnis ist irgendwo zwischen 25% und 70%.
Wir haben keine Inline CSS-Code gefunden. Es ist gut.
Alle SEO Webmaster denken Sie CSS in einer CSS-Datei, nicht im HTML verwenden müssen. Wir wissen, dass manchmal Inline-CSS ist nützlich und sehr schnell wieder Stil einen Absatz, ein div oder ein HTML-Element. Es ist jedoch eine bessere Lösung, um Ihre CSS-Code in einer anderen Datei schreiben.
Wir haben einen Iframe gefunden. Es ist nicht gut.
Sie können iframe-Tag laden Inhalte von anderen Seiten verwenden, aber einige Suchmaschinen die Verwendung von iframes nicht versteht. So müssen Sie wissen, dass der Inhalt von einem Iframe geladen wird nicht indiziert. Wir schlagen nicht iframes oder Frames verwenden.
Wir haben keine Rahmen gefunden. Es ist gut.
Seite charset ist UTF-8.Insgesamt sind 1062Schlüsselwörter. Anzahl der Links 293, 282 von eingehenden Links und 11 der ausgehenden Links. Unsere Seite Analysator hat gezeigt, dass www.afinitor.de ist wie folgt:
Codierung
Charset der Seite
UTF-8
Keyword-Dichte
insgesamt Keywords
1062
Anzahl der Links
Insgesamt Links Website
293
Eingehende Links von Website
282
Outbound Links Website
11
Nofollow links
0
Anchor text
Type
Link
Skip to main content
follow
#main-content
follow
/
follow
About
follow
/about
Board of Directors
follow
/about/board-directors
Joerg Reinhardt
follow
/about/board-directors/joerg-reinhardt
Enrico Vanni
follow
/about/board-directors/enrico-vanni
Nancy Andrews
follow
/about/board-directors/nancy-andrews
Ton Buechner
follow
/about/board-directors/ton-buechner
Patrice Bula
follow
/about/board-directors/patrice-bula
Elizabeth Doherty
follow
/about/board-directors/elizabeth-doherty
Ann Fudge
follow
/about/board-directors/ann-fudge
Bridgette Heller
follow
/about/board-directors/bridgette-heller
Frans van Houten
follow
/about/board-directors/frans-van-houten
Simon Moroney
follow
/about/board-directors/simon-moroney
Andreas von Planta
follow
/about/board-directors/andreas-von-planta
Charles Sawyers
follow
/about/board-directors/charles-sawyers
William Winters
follow
/about/board-directors/william-winters
Charlotte Pamer-Wieser
follow
/about/board-directors/charlotte-pamer-wieser
Executive Committee
follow
/about/executive-committee
Vasant Narasimhan
follow
/about/executive-committee/vasant-narasimhan
James Bradner
follow
/about/executive-committee/james-bradner
Karen Hale
follow
/about/executive-committee/karen-hale
Harry Kirsch
follow
/about/executive-committee/harry-kirsch
Steffen Lang
follow
/about/executive-committee/steffen-lang
Klaus Moosmayer
follow
/about/executive-committee/klaus-moosmayer
Richard Saynor
follow
/about/executive-committee/richard-saynor
Susanne Schaffert
follow
/about/executive-committee/susanne-schaffert
John Tsai
follow
/about/executive-committee/john-tsai
Marie-France Tschudin
follow
/about/executive-committee/marie-france-tschudin
Robert Weltevreden
follow
/about/executive-committee/robert-weltevreden
Lutz Hegemann
follow
/about/executive-committee/lutz-hegemann
Natacha Theytaz
follow
/about/executive-committee/natacha-theytaz
Michael Willi
follow
/about/executive-committee/michael-willi
Rob Kowalski
follow
/about/executive-committee/rob-kowalski
Strategy
follow
/about/strategy
People and Culture
follow
/about/strategy/people-and-culture
Data and Digital
follow
/about/strategy/data-and-digital
Products
follow
/about/products
Innovative Medicines
follow
/about/innovative-medicines
Novartis Oncology
follow
/about/innovative-medicines/novartis-oncology
Novartis Pharmaceuticals
follow
/about/innovative-medicines/novartis-pharmaceuticals
Sandoz
follow
https://www.sandoz.com/
Diversity & Inclusion
follow
/about/diversity-inclusion
Equity
follow
/about/diversity-inclusion/equity
Diversity & Inclusion Governance and Community
follow
/about/diversity-inclusion/diversity-inclusion-governance-and-community
Inclusivity
follow
/about/diversity-inclusion/inclusivity
Parental Leave
follow
/about/diversity-inclusion/parental-leave
Society
follow
/about/diversity-inclusion/society
Quality
follow
/about/quality
Audit program
follow
/about/quality/audit-program
Novartis Quality Management System (QMS)
follow
/about/quality/novartis-quality-management-system-qms
Product and patient safety training
follow
/about/quality/product-and-patient-safety-training
Regulatory inspections
follow
/about/quality/regulatory-inspections
Product recalls
follow
/about/quality/product-recalls
Third-party suppliers
follow
/about/quality/third-party-suppliers
follow
/about-novartis
follow
About Novartis
follow
/about-novartis
Patients and Caregivers
follow
/patients-and-caregivers
Novartis Commitment to Patients and Caregivers
follow
/patients-and-caregivers/novartis-commitment-patients-and-caregivers
Diseases
follow
/diseases
Patient Organization Funding
follow
/esg/reporting/transparency-and-disclosure/patient-organization-funding
Adverse Event Reporting
follow
https://www.report.novartis.com/
COVID-19: Patients and Caregivers
follow
/coronavirus/patients-caregivers
Stories: Patients Perspectives
follow
/news/stories/patient-perspectives
follow
/patients-and-caregivers
follow
Patients & Caregivers
follow
/patients-and-caregivers
Healthcare Professionals
follow
/healthcare-professionals
Medical Congresses and Events
follow
/healthcare-professionals/medical-congresses-and-events
Abstract summaries for EULAR
follow
/healthcare-professionals/medical-congresses-and-events/abstract-summaries-eular
Abstract summaries for ACR
follow
/healthcare-professionals/medical-congresses-and-events/abstract-summaries-acr
Abstract summaries for EADV
follow
/healthcare-professionals/medical-congresses-and-events/abstract-summaries-eadv
Products
follow
/about/products
Novartis Pipeline
follow
/research-development/novartis-pipeline
Managed Access Programs
follow
/healthcare-professionals/managed-access-programs
Novartis Gene Therapies Managed Access Program
follow
/healthcare-professionals/managed-access-programs/novartis-gene-therapies-managed-access-program
Novartis External Funding
follow
/healthcare-professionals/novartis-external-funding
Healthcare Professional Resources by Country
follow
/healthcare-professionals/healthcare-professional-resources-country
Investigator-Initiated Trials / Studies
follow
/healthcare-professionals/investigator-initiated-trials-studies
Transparency and Disclosure
follow
/esg/reporting/transparency-and-disclosure
follow
/healthcare-professionals
follow
Healthcare Professionals
follow
/healthcare-professionals
Research & Development
follow
/research-development
Novartis Institutes for BioMedical Research
follow
/research-development/novartis-institutes-biomedical-research
Collaborations
follow
/research-development/novartis-institutes-biomedical-research/collaborations
Technology Platforms
follow
/research-development/technology-platforms
Radioligand Therapy
follow
/research-development/technology-platforms/radioligand-therapy
Gene Therapy
follow
/research-development/technology-platforms/gene-therapy
Cell Therapy
follow
/research-development/technology-platforms/cell-therapy
Research Disease Areas
follow
/research-development/research-disease-areas
Immuno-oncology research at Novartis
follow
/research-development/research-disease-areas/immuno-oncology-research-novartis
Oncology research at Novartis
follow
/research-development/research-disease-areas/oncology-research-novartis
Cardiovascular and metabolic disease research at Novartis
follow
/research-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis
Autoimmunity, transplantation and inflammatory disease research at Novartis
follow
/research-development/research-disease-areas/autoimmunity-transplantation-and-inflammatory-disease-research-novartis
Ophthalmology research at Novartis
follow
/research-development/research-disease-areas/ophthalmology-research-novartis
Neuroscience Research at Novartis
follow
/research-development/research-disease-areas/neuroscience-research-novartis
Musculoskeletal Disease Research at Novartis
follow
/research-development/research-disease-areas/musculoskeletal-disease-research-novartis
DAx: exploratory disease research at Novartis
follow
/research-development/research-disease-areas/dax-exploratory-disease-research-novartis
Research Locations
follow
/research-development/research-locations
Novartis Institute for Tropical Diseases
follow
/research-development/research-locations/novartis-institute-tropical-diseases
Novartis Pipeline
follow
/research-development/novartis-pipeline
Translational Medicine
follow
/research-development/translational-medicine-research-novartis
Research & Development Approach
follow
/research-development/research-development-approach
Stories from our Labs
follow
/news/stories/from-our-labs
Open Source Science
follow
/research-development/open-source-science
follow
/research-development
follow
Research & Development
follow
/research-development
ESG
follow
/esg
Access
follow
/esg/access
Creating sustainable business models
follow
/esg/access/creating-sustainable-business-models
Value-Based Pricing
follow
/esg/access/value-based-pricing
Sub-Saharan Africa
follow
/esg/access/sub-saharan-africa
Donations
follow
/esg/access/donations
Novartis Access Principles
follow
/esg/access/novartis-access-principles
Novartis Oncology Access
follow
/esg/access/novartis-oncology-access
Patents and Licensing
follow
/esg/access/patents-and-licensing
Ethics, Risk and Compliance
follow
/esg/ethics-risk-and-compliance
Ethical Behavior
follow
/esg/ethics-risk-and-compliance/ethical-behavior
Compliance
follow
/esg/ethics-risk-and-compliance/compliance
Human Rights
follow
/esg/ethics-risk-and-compliance/human-rights
Learning and Engagement
follow
/esg/ethics-risk-and-compliance/learning-and-engagement
Risk management
follow
/esg/ethics-risk-and-compliance/risk-management
Environmental Sustainability
follow
/esg/environmental-sustainability
Climate
follow
/esg/environmental-sustainability/climate
Waste
follow
/esg/environmental-sustainability/waste
Water
follow
/esg/environmental-sustainability/water
Global Health
follow
/esg/global-health
Chagas Disease
follow
/diseases/chagas-disease
Leprosy
follow
/diseases/leprosy
Malaria
follow
/diseases/malaria
Sickle Cell Disease (SCD)
follow
/diseases/sickle-cell-disease
Novartis Foundation
follow
https://www.novartisfoundation.org/
Diversity & Inclusion
follow
/about/diversity-inclusion
Reporting
follow
/esg/reporting
Environmental, Social and Governance (ESG) Index
follow
/esg/reporting/esg-index
ESG Rating Performance
follow
/esg/reporting/esg-rating-performance
Codes, Policies and Guidelines
follow
/esg/reporting/codes-policies-and-guidelines
Materiality Assessment
follow
/esg/reporting/materiality-assessment
Transparency and Disclosure
follow
/esg/reporting/transparency-and-disclosure
Targets
follow
/esg/reporting/targets
ESG Publications
follow
/esg/reporting/esg-publications
Positions
follow
/esg/reporting/positions
Reporting Archive
follow
/esg/reporting/reporting-archive
follow
/environmental-social-and-governance
follow
Environmental, Social and Governance
follow
/environmental-social-and-governance
Investors
follow
/investors
Event Calendar
follow
/investors/event-calendar
Financial Data
follow
/investors/financial-data
Novartis Annual Results
follow
/investors/financial-data/annual-results
Novartis Quarterly Results
follow
/investors/financial-data/quarterly-results
Novartis SEC Filings
follow
/investors/financial-data/sec-filings
Product Sales
follow
/investors/financial-data/product-sales
Fixed-Income Securities
follow
/investors/financial-data/fixed-income-securities
Expected Currency Impact
follow
/investors/financial-data/expected-currency-impact
Share Data & Analysis
follow
/investors/share-data-analysis
Share Monitor
follow
/investors/share-data-analysis/share-monitor
Return On Investment Calculator
follow
/investors/share-data-analysis/return-investment-calculator
Dividend Information
follow
/investors/share-data-analysis/dividend-information
Share Ownership
follow
/investors/share-data-analysis/share-ownership
Share Overview
follow
/investors/share-data-analysis/share-overview
Shareholder Information
follow
/investors/shareholder-information
Annual General Meeting of Shareholders
follow
/investors/shareholder-information/annual-general-meeting
Novartis Registered Shares
follow
/investors/shareholder-information/novartis-registered-shares
American Depository Receipts (ADR)
follow
/investors/shareholder-information/american-depository-receipts-adr
Share Buy-Back
follow
/investors/shareholder-information/share-buy-back
Frequently Asked Questions
follow
/investors/shareholder-information/frequently-asked-questions
Company Overview
follow
/investors/company-overview
Corporate Governance
follow
/investors/company-overview/corporate-governance
Novartis Annual Reporting Suite
follow
/investors/novartis-annual-reporting-suite
Annual Reports Archive
follow
/investors/novartis-annual-reporting-suite/annual-reports-archive
Publications Order Form
follow
/news/stay-up-to-date
ESG
follow
/esg
follow
/investors
follow
Investors
follow
/investors
News
follow
/news
News Archive
follow
/news/news-archive
Media Library
follow
/news/media-library
Stories
follow
/stories
Subscribe
follow
/news/stay-up-to-date
follow
/news
follow
News
follow
/news
Careers
follow
/careers
Career Search
follow
/careers/career-search
Our Teams
follow
/careers/our-teams
Careers in Commercial
follow
/careers/our-teams/careers-commercial
Careers in Communications and Advocacy
follow
/careers/our-teams/careers-communications-and-advocacy
Careers in Consulting
follow
/careers/our-teams/careers-consulting
Careers in Digital
follow
/careers/our-teams/careers-digital
Careers in Health, Safety & Environment
follow
/careers/our-teams/careers-health-safety-environment
Careers in Information Technology (IT)
follow
/careers/our-teams/careers-information-technology-it
Careers in Medical & Development
follow
/careers/our-teams/careers-medical-development
Careers in People & Organization
follow
/careers/our-teams/careers-people-organization
Careers in Procurement
follow
/careers/our-teams/careers-procurement
Careers in Research
follow
/careers/our-teams/careers-research
Careers in Strategy
follow
/careers/our-teams/careers-strategy
Careers in Technical Operations
follow
/careers/our-teams/careers-technical-operations
Ethics, Risk & Compliance (ERC)
follow
/careers/our-teams/ethics-risk-compliance-erc
Careers in Legal
follow
/careers/our-teams/careers-legal
Career Programs
follow
/careers/career-programs
Community Exploration & Learning Lab (CELL)
follow
/careers/career-programs/community-exploration-learning-lab-cell
Early Talent
follow
/careers/early-talent
Postdoc Program
follow
/careers/postdoc-program
Andreas Bender, PhD
follow
/careers/postdoc-program/andreas-bender-phd
Boxun Lu, PhD
follow
/careers/postdoc-program/boxun-lu-phd
The Novartis Innovation Postdoctoral Fellowship
follow
/careers/postdoc-program/novartis-innovation-postdoctoral-fellowship
The Novartis Discovery Postdoctoral Fellowship
follow
/careers/postdoc-program/novartis-discovery-postdoctoral-fellowship
Postdoc Research Themes
follow
/careers/postdoc-program/postdoc-research-themes
Recognition
follow
/careers/postdoc-program/recognition
Postdoc Program Leadership
follow
/careers/postdoc-program/postdoc-program-leadership
International Careers
follow
/careers/international-careers
Learning and Development
follow
/careers/learning-and-development
NIBR Global Scholars Program
follow
/careers/nibr-global-scholars-program
Well-being
follow
/careers/well-being
Internship Programs
follow
/careers/internship-programs
follow
/careers
follow
Careers
follow
/careers
COVID-19 Information Center
follow
/coronavirus
follow
/media-library/covid-19-novartis-response
follow
COVID-19 Novartis response
follow
/media-library/covid-19-novartis-response
Clinical Trials
follow
/clinicaltrials
follow
/clinicaltrials
follow
Clinical Trials
follow
/clinicaltrials
Partnering
follow
/partnering
follow
/partnering
follow
Partnering
follow
/partnering
Contacts
follow
/contacts
follow
/contacts
follow
Contacts
follow
/contacts
follow
/home
follow
Home
follow
/home
Previous
follow
#paragraph--2146
Next
follow
#paragraph--2146
follow
About NovartisWe discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
follow
/about
AccessWe are committed to bringing more of our medicines to more people, no matter where they are. For all our new medicines, we will systematically integrate access strategies in how we research, develop and deliver globally.
follow
/esg/access
Research & DevelopmentWe are exploring possibilities to cure disease, intervene earlier in chronic illnesses, and find ways to improve and extend people’s lives.
follow
/research-development
Learn More
follow
/research-development
Read More
follow
/stories/make-difference-start-patients
Read More
follow
/stories/toward-regrowing-cartilage
Expanding a new digital healthcare solution
follow
/stories/expanding-new-digital-healthcare-solution-across-chronic-heart-disease-management
Read the Story
follow
/stories/expanding-new-digital-healthcare-solution-across-chronic-heart-disease-management
Previous
follow
#paragraph--37081
Next
follow
#paragraph--37081
Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021
follow
/news/media-releases/novartis-presents-positive-phase-iii-results-cosentyx-children-active-enthesitis-related-arthritis-era-and-juvenile-psoriatic-arthritis-jpsa-acr-2021
Novartis announces new publication in Cephalalgia of data showcasing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention
follow
/news/media-releases/novartis-announces-new-publication-cephalalgia-data-showcasing-superior-tolerability-and-efficacy-aimovig-erenumab-compared-topiramate-migraine-prevention
Leqvio®* (inclisiran) reduced LDL-C in people who are overweight or obese
follow
/news/media-releases/leqvio-inclisiran-reduced-ldl-c-people-who-are-overweight-or-obese
All News
follow
/news/news-archive?type=media_release
Novartis Financial Results – Q3 2021Novartis announced the company’s financial results for the third quarter of 2021.
follow
/news/novartis-financial-results-q3-2021
Novartis COVID-19 Information CenterNovartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.
follow
/coronavirus
The Novartis Commitment to Patients and CaregiversNovartis works with the patient community around the world to discover new ways to improve and extend people’s lives.
follow
/patients-and-caregivers/novartis-commitment-patients-and-caregivers
People and CultureNovartis is building an Inspired, Curious and Unbossed culture.
follow
/about/strategy/people-and-culture
Live MagazineLive is the in-house magazine of Novartis which is now available in a digital format. Explore stories, podcasts and more from across the company.
follow
https://live.novartis.com
Learn More
follow
/esg
Patients and Caregivers
follow
/patients-and-caregivers
Healthcare Professionals
follow
/healthcare-professionals
Researchers
follow
/research-development
Job Seekers
follow
/careers
Journalists
follow
/news
Investors
follow
/investors
Partners
follow
/partnering
Suppliers
follow
/supplier-portal
Clinical Trials
follow
/clinicaltrials
COVID-19 Info Center
follow
/coronavirus
ESG
follow
/esg
Stories
follow
/stories
Diseases
follow
/diseases
Locations
follow
/about/locations
Sandoz
follow
https://www.sandoz.com
Advanced Accelerator Applications
follow
https://www.adacap.com/
follow
https://www.twitter.com/novartis
follow
https://www.linkedin.com/company/novartis
follow
https://www.youtube.com/user/Novartis
follow
https://www.facebook.com/novartis
follow
https://www.instagram.com/novartis
Terms of Use
follow
/terms-use
Privacy
follow
/privacy
Contacts
follow
/contacts
Cookie Settings
follow
#cookie-settings-button
Site Map
follow
/sitemap.xml
Novartis Site Directory
follow
/novartis-directory
Meta-Variablen
Title:
Novartis
news_keywords
, novartis,
generator
Drupal 9 (https://www.drupal.org)
description
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
keywords
novartis
Novartis
Website
https://www.novartis.com/home
Home
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
https://www.novartis.com/sites/novartis_com/files/novartis-logo-open-graph.jpg
https://www.novartis.com/sites/novartis_com/files/novartis-logo-open-graph.jpg
https://www.novartis.com/sites/novartis_com/files/novartis-logo-open-graph.jpg
Novartis logo
google-site-verification
twitter:card
summary_large_image
twitter:description
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
twitter:site
@novartis
twitter:title
Home
twitter:site:id
17226612
twitter:creator
@novartis
twitter:creator:id
17226612
twitter:url
https://www.novartis.com/home
twitter:image:alt
Novartis logo
twitter:image
https://www.novartis.com/sites/novartis_com/files/novartis-logo-open-graph.jpg
Generator
Drupal 9 (https://www.drupal.org)
MobileOptimized
width
HandheldFriendly
true
viewport
width=device-width, initial-scale=1, shrink-to-fit=no
ie=edge
layout-one-sidebar layout-sidebar-second has-featured-top page-node-141 path-frontpage node--type-interior-page blue_pattern blue_box_carbon_pattern alert_popup_show_once content-home, visually-hidden focusable skip-link, dialog-off-canvas-main-canvas, arc-fixed, alert-banner-region, header, full-width-navbar, navbar navbar-expand-lg, navbar-brand, img-fluid d-inline-block align-top novartis-logo, novartis_whole_menu, block block-menu navigation menu--account, accordion_item_wrapper accordion-stripe-close, sr-only, accordion-stripe-body, clearfix nav simple-menu, nav-item search, nav-link nav-link-, nav-item menu, block block-we-megamenu block-we-megamenu-blockmain, content, region-we-mega-menu, navbar-toggle collapsed, icon-bar, main navbar navbar-default navbar-we-mega-menu mobile-collapse hover-action, container-fluid, we-mega-menu-ul nav nav-tabs, we-mega-menu-li dropdown-menu, we-mega-menu-li, we-mega-menu-submenu, more_from, we-mega-menu-submenu-inner, we-mega-menu-row, we-mega-menu-col span6, nav nav-tabs subul, we-mega-menu-col span12, type-of-block, block-inner, megamenu-content-block, section-image, section-name, section-content, we-mega-menu-li dropdown-menu single-item, we-mega-menu-li single-item dropdown-menu single-item, we-mega-right, layout-main-wrapper background_blue text_clr_white clearfix, highlighted, container section clearfix, hidden, featured-top, featured-top__inner section container clearfix, row region region-featured-top, views-exposed-form block block-views block-views-exposed-filter-blockglobal-search-global-search, wrap-global-search-result container, arctic-daterange, start litepicker-input, js-form-item js-form-type-search-api-autocomplete form-type-search-api-autocomplete js-form-item-keyword form-item-keyword form-no-label form-group, form-autocomplete form-text form-control arc-input, js-form-item js-form-type-select form-type-select js-form-item-section form-item-section form-group, form-select form-control, form-actions js-form-wrapper form-group, button js-form-submit form-submit btn btn-primary form-control arc-input, field field--name-field-header field--type-entity-reference-revisions field--label-above, field__label, field__items, field__item, paragraph paragraph--type--slideshow-carousel paragraph--view-mode--default, carousel slide , carousel-inner, large carousel-item active , carousel_img_video, field field--name-field-image field--type-image field--label-hidden field__item, img img-fluid, carousel-caption d-md-block content_box left , container, carousel_inner--wrapper , stripe_title , carousel-control-prev, carousel-control-prev-icon, carousel-control-next, carousel-control-next-icon, background_stripe, block block-system block-system-breadcrumb-block, container-fluid custom_width, row row-offcanvas row-offcanvas-left clearfix, main-content col order-last col-md-12 main-content col order-last column-full, section, block block-system block-system-main-block, node node--type-interior-page node--view-mode-full clearfix, node__content clearfix, page_content, row content_middle, col-sm-12 content_left_side, field_body_txt, field field--name-field-body field--type-entity-reference-revisions field--label-hidden field__items, paragraph paragraph--type--cards paragraph--view-mode--default, field field--name-field-card-type field--type-entity-reference-revisions field--label-hidden field__items, paragraph paragraph--type--_-columns-equal-size-card-stripe paragraph--view-mode--default, row common-card-wrapper, card_wrapper card_base col-md-6 col-lg-4, card_type_full, card_img, video-content, field field--name-field-card-col1 field--type-entity-reference-revisions field--label-hidden field__item, img-wrapper, card_content, card_title , basic_paragraph, field field--name-field-card-col2 field--type-entity-reference-revisions field--label-hidden field__item, field field--name-field-card-col3 field--type-entity-reference-revisions field--label-hidden field__item, paragraph paragraph--type--media-content paragraph--view-mode--default, row background_white text_clr_black text-on-left-side, col-lg-6 order-lg-2 media_stripe_img, field field--name-field-document-public-file field--type-entity-reference field--label-hidden field__item, field field--name-field-media-video-embed-field field--type-video-embed-field field--label-hidden field__item, video-embed-field-provider-kaltura video-embed-field-responsive-video, kalura-kwidget-content, col-lg-6 order-lg-1 media_stripe_text, stripe_subtitle, grid_class_cta_wrapper, field field--name-field-cta-text-and-url field--type-entity-reference-revisions field--label-hidden field__items, cta-teaser, cta_title , cta_description, link_button button_text, row background_white text_clr_black text-on-right-side, col-lg-6 order-lg-1 media_stripe_img, col-lg-6 order-lg-2 media_stripe_text, grid_class_cta_wrapper grid_class_button_wrapper, field field--name-field-button-text-and-url field--type-entity-reference-revisions field--label-hidden field__item, cta-teaser button-teaser mb-3 mt-3, stripe_title, , carousel_desc, carousel_link_button, button_text element_margin, paragraph paragraph--type--media-release paragraph--view-mode--default, media_release_main_title , field field--name-field-media-releases-list field--type-entity-reference field--label-hidden field__items, media-releases-container, media-releases-list row, media-releases-item col-lg-4 col-md-6 col-sm-12, media_meta_content_wrapper, meta_content, link_button_wrapper, button_text element_margin link_button, paragraph paragraph--type--_-columns-1-2-and-1-2-card paragraph--view-mode--default, card_wrapper card_base col-md-6, clearfix text-formatted field field--name-field-cta-description field--type-text-with-summary field--label-hidden field__item, content_bottom, site-footer, row region region-footer-menu, block block-block-content block-block-contentf15c8c31-8ede-4e83-9fdd-344ea44dcd35, footer-widgets, row, col-lg-3, row region region-footer-first, block block-menu navigation menu--navigate-to-novartis, accordion-stripe-title, footer-nav-links, clearfix nav, nav-item, nav-link nav-link--patients-and-caregivers, nav-link nav-link--healthcare-professionals, nav-link nav-link--research-development, nav-link nav-link--careers, nav-link nav-link--news, nav-link nav-link--investors, nav-link nav-link--partnering, nav-link nav-link--supplier-portal, row region region-footer-second, block block-menu navigation menu--about-novartis, nav-link nav-link--clinicaltrials, nav-link nav-link--coronavirus, nav-link nav-link--esg, row region region-footer-third, block block-menu navigation menu--contact-us, nav-link nav-link--stories, nav-link nav-link--diseases, nav-link nav-link--about-locations, row region region-footer-fourth, block block-menu navigation menu--our-portfolio, nav-link nav-link-https--wwwsandozcom, nav-link nav-link-https--wwwadacapcom-, footer-widgets middle-footer-section, col-lg-5 middle_footer_left, row region region-footer-middle-first, block-social-media-links block block-social-media-links-block, social-media-links--platforms platforms inline horizontal, social-media-link-icon--twitter, fa fa-twitter fa-2x, social-media-link-icon--linkedin, fa fa-linkedin fa-2x, social-media-link-icon--youtube, fa fa-youtube fa-2x, social-media-link-icon--facebook, fa fa-facebook fa-2x, social-media-link-icon--instagram, fa fa-instagram fa-2x, col-lg-6 offset-lg-1 middle_footer_right, row region region-footer-middle-second, search-block-form block block-arctic-search block-search-form-block, search-form search-block-form form-row, js-form-item js-form-type-textfield form-type-textfield js-form-item-keyword form-item-keyword form-no-label form-group, form-text form-control arc-input, footer_bottom, row region region-footer-bottom, block block-menu navigation menu--footer-bottom, row footer-bottom-section, col-lg-8, novartis-text, bottom-organsim, clearfix nav navbar-nav, nav-link nav-link--terms-use, nav-link nav-link--privacy, nav-link nav-link--contacts, ot-sdk-show-settings nav-link ot-sdk-show-settings ot-sdk-show-settings ot-sdk-show-settings nav-link-cookie-settings-button, nav-link nav-link--sitemapxml, col-lg-4, site_directory, globe-icon, dir-text, novartis-text-global,
- ontvtime.ru (ТВ онлайн | Прямой эфир Архивы | Онлайн телевидение)
- pinimg.com (Pinterest)
- dkv-aachen.de (Günstige Kfz-Versicherung in Aachen | ERGO)
- dkfk.de (dkfk.de est disponible à l´achat - Sedo.com)
- czech-tourist.de (Czech Tourist - das Infoportal für Tschechien: Tourismus, Kurbäder, Sport, Kultur, Ferienhäuser)
- cnccc.de (RC Systems )
- carolinschmidt.de (Dr Carolin Schmidt)
- btb-helmrich.de (STRATO - Domain reserved)
- bgnr.de (bgnr.de)
- bgfb.de (bgfb Besteckverleih Gläserverleih Frontladerspülmaschine Besteckpoliermaschine Spülmobil Verleih Geschirrmobil Mieten)